We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 92.61%
2 Real Estate 3%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.7B
$26.5M 1.01%
269,769
-9,650
-3% -$864K
TEVA icon
27
Teva Pharmaceuticals
TEVA
$41.2B
$26.4M 1%
1,083,843
+620
+0.1% +$12.6K
ELV icon
28
Elevance Health
ELV
$81.6B
$26.3M 1%
110,633
+19,151
+21% +$4.43M
XBI icon
29
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$23.8M 0.9%
250,460
– –
CVS icon
30
CVS Health
CVS
$134B
$23.6M 0.9%
366,521
– –
SYK icon
31
Stryker
SYK
$133B
$23.1M 0.88%
136,631
+72,373
+113% +$12.2M
CNC icon
32
Centene
CNC
$30.1B
$22.8M 0.86%
369,638
-90,678
-20% -$5.23M
SAGE
33
DELISTED
Sage Therapeutics
SAGE
$22.5M 0.85%
143,614
+18,964
+15% +$2.98M
NVS icon
34
Novartis
NVS
$301B
$22.3M 0.85%
330,135
-61,603
-16% -$4.25M
DHR icon
35
Danaher
DHR
$138B
$19M 0.72%
217,558
+133,131
+158% +$11.9M
JAZZ icon
36
Jazz Pharmaceuticals
JAZZ
$16.2B
$19M 0.72%
110,452
-12,030
-10% -$1.97M
SGEN
37
DELISTED
Seagen Inc. Common Stock
SGEN
$18.6M 0.7%
279,417
-67,082
-19% -$3.84M
OHI icon
38
Omega Healthcare
OHI
$15B
$18M 0.68%
579,785
– –
AET
39
DELISTED
Aetna Inc
AET
$17.8M 0.68%
97,122
+49,556
+104% +$8.83M
SBRA icon
40
Sabra Healthcare REIT
SBRA
$5.38B
$15.7M 0.6%
724,606
– –
BSX icon
41
Boston Scientific
BSX
$68.4B
$15M 0.57%
457,585
– –
GSK icon
42
GSK
GSK
$104B
$14.5M 0.55%
287,200
-28,599
-9% -$1.44M
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$13.7M 0.52%
875,304
– –
ZBH icon
44
Zimmer Biomet
ZBH
$18.4B
$13.2M 0.5%
122,411
+37,869
+45% +$4.12M
BMRN icon
45
BioMarin Pharmaceuticals
BMRN
$11.7B
$13.2M 0.5%
140,538
-140,538
-50% -$12.3M
MCK icon
46
McKesson
MCK
$101B
$13.2M 0.5%
98,797
– –
ALNY icon
47
Alnylam Pharmaceuticals
ALNY
$27.4B
$12.8M 0.49%
130,376
– –
BDX icon
48
Becton Dickinson
BDX
$45.6B
$12.7M 0.48%
54,302
+36,617
+207% +$8.15M
MPT
49
Medical Properties Trust
MPT
$2.81B
$12.1M 0.46%
858,586
– –
WELL.PRI
50
DELISTED
Welltower Inc.
WELL.PRI
$11.9M 0.45%
200,000
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.